Piramal Pharma Limited — PPTs, 29-07-2026: Investor Presentation

Piramal Pharma kicked off FY27 strongly, reporting consolidated revenue of ₹2,270 Cr, up 17% YoY. EBITDA surged 72% to ₹285 Cr, with margins expanding 400 bps to 12.5%, reflecting improved operations. Net loss improved by 15% to ₹69 Cr.

All three segments showed robust growth: CDMO revenue grew 19% to ₹1,187 Cr, driven by strong order inflows and execution. Complex Hospital Generics (CHG) revenue rose 17% to ₹743 Cr, maintaining leadership in key therapies. Piramal Consumer Healthcare (PCH) revenue increased 15% to ₹347 Cr, powered by Power Brands (+23%) and e-commerce (+40%).

Key strategic moves include strengthening CDMO capabilities with the launch of a commercial-scale payload-linker suite at Riverview (US) and a new conjugation tech partnership. CHG anticipates Kenalog supplies from Q2FY27. PCH launched the 'i-choose' master brand and continues significant brand investments.

Management expects sustained revenue growth and EBITDA expansion throughout FY27, emphasizing agile execution in a dynamic market.